0001209191-20-051403.txt : 20200922
0001209191-20-051403.hdr.sgml : 20200922
20200922110947
ACCESSION NUMBER: 0001209191-20-051403
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200918
FILED AS OF DATE: 20200922
DATE AS OF CHANGE: 20200922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burow Kristina
CENTRAL INDEX KEY: 0001569248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39512
FILM NUMBER: 201188399
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Metacrine, Inc.
CENTRAL INDEX KEY: 0001634379
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472297384
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-369-7800
MAIL ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-18
0
0001634379
Metacrine, Inc.
MTCR
0001569248
Burow Kristina
C/O ARCH VENTURE FUND VIII, L.P.
8755 WEST HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
0
0
Common Stock
2020-09-18
4
C
0
1960784
A
1960784
I
See footnote
Common Stock
2020-09-18
4
C
0
472251
A
2433035
I
See footnote
Common Stock
2020-09-18
4
C
0
138734
A
2571769
I
See footnote
Common Stock
2020-09-18
4
P
0
210000
13.00
A
2781769
I
See footnote
Common Stock
2020-09-18
4
C
0
138734
A
138734
I
See footnote
Common Stock
2020-09-18
4
P
0
20000
13.00
A
158734
I
See footnote
Series A Convertible Preferred Stock
2020-09-18
4
C
0
1960784
D
Common Stock
1960784
0
I
See footnote
Series B Convertible Preferred Stock
2020-09-18
4
C
0
472251
D
Common Stock
472251
0
I
See footnote
Series C Convertible Preferred Stock
2020-09-18
4
C
0
138734
D
Common Stock
138734
0
I
See footnote
Series C Convertible Preferred Stock
2020-09-18
4
C
0
138734
D
Common Stock
138734
0
I
See footnote
Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH
Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole
general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the
shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of
any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may
be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such
shares, except to the extent of any pecuniary interest therein.
The Reporting Person has an interest in ARCH Partners VIII and ARCH VIII LLC but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund
Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims
beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith
L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs.
Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The Reporting Person has an interest in ARCH VIII LLC but does not have voting or investment control over the shares held by ARCH Fund Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
Kristina Burow, Managing Director By: /s/ Mark McDonnell, as Attorney-in-Fact
2020-09-22